In clear contrast to anti-PD-1 monotherapy, treatment with SAM+anti-PD-1 showed significant reduction in tumor growth and enhanced anticancer immunity even in a setting with fewer injections of anti-PD-1, where monotherapy alone fails to induce protection. Here, PDCD1 is linked to neoplasm.